46 interactions on record
Fluvoxamine, a strong CYP1A2 inhibitor, increased alosetron AUC approximately 6-fold and prolonged half-life approximately 3-fold. Concomitant use is contraindicated.
Source: NLP:alosetron hydrochloride
Moderate CYP 3A4 inhibitor; should not be co-administered with methylergonovine to avoid vasospasm risk.
Source: NLP:methylergonovine maleate
Strong CYP1A2 inhibitor that significantly increases pirfenidone exposure. Should be discontinued prior to pirfenidone administration and avoided during treatment.
Source: NLP:pirfenidone
Strong CYP1A2 inhibitor that increases ramelteon AUC approximately 190-fold and Cmax approximately 70-fold; should not be used in combination.
Source: NLP:ramelteon
Increases thioridazine and active metabolites (mesoridazine, sulforidazine) 3-fold. Should not be coadministered.
Source: NLP:thioridazine hydrochloride
Concomitant use is contraindicated. Results in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.
Source: NLP:tizanidine
Strong CYP1A2 inhibitor causing significantly decreased blood pressure, increased drowsiness, and psychomotor impairment when combined with tizanidine.
Source: NLP:tizanidine hydrochloride
Strong CYP1A2 inhibitor; concomitant use contraindicated due to significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.
Source: NLP:tizanidne hydrochloride
SSRI that inhibits P450 2D6 and P450 1A2, both involved in clomipramine metabolism, may increase plasma levels.
Source: NLP:clomipramine hydrochloride
Strong CYP1A2 inhibitor that increases clozapine plasma levels, potentially resulting in adverse reactions. Requires dose reduction to one-third.
Source: NLP:clozapine
Inhibits hepatic enzymes (CYP3A and 2C19), leading to increased and prolonged sedation.
Source: NLP:diazepam
Potent CYP1A2 inhibitor increased duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and half-life approximately 3-fold. Should be avoided.
Source: NLP:duloxetine
Potent CYP1A2 inhibitor increases duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and t1/2 approximately 3-fold.
Source: NLP:duloxetine d/r
Potent CYP1A2 inhibitor increases duloxetine AUC approximately 6-fold, Cmax about 2.5-fold, and t1/2 approximately 3-fold.
Source: NLP:duloxetine hydrochloride
CYP1A2 inhibitor that increases lidocaine plasma AUC by 71% and Cmax by 22%, decreases clearance by 41%-60%, and prolongs half-life by one hour.
Source: NLP:lidocaine hydrochloride
SSRI and CYP2C19/CYP3A4 inhibitor that increases methadone plasma concentration, resulting in increased opioid effects and risk of fatal overdose.
Source: NLP:methadone hydrochloride
Strong CYP1A2 inhibitor that increased pomalidomide Cmax by 24% and AUC by 125%, increasing risk of exposure-related toxicities. Avoid concomitant use; if unavoidable, reduce pomalidomide dose.
Source: NLP:pomalidomide
Strong CYP1A2 inhibitor reduced plasma clearance of ropivacaine by 70%, leading to increased ropivacaine plasma levels.
Source: NLP:ropivacaine hydrochloride
Strong CYP1A2 inhibitor that increases tasimelteon exposure, potentially causing a large increase in drug levels and greater risk of adverse reactions.
Source: NLP:tasimelteon
Inhibitor of CYP2C9 and CYP1A2 that increases warfarin effect and INR; requires close INR monitoring
Source: NLP:warfarin
CYP2C9 and CYP1A2 inhibitor that increases warfarin effect and INR; requires closer INR monitoring.
Source: NLP:warfarin sodium
Moderate CYP3A inhibitor may increase alprazolam concentrations; avoid use or consider dose reduction.
Source: NLP:alprazolam
CYP1A2 inhibitor may increase anagrelide exposure; monitor for cardiovascular events and titrate dose accordingly.
Source: NLP:anagrelide
CYP1A2 inhibitor may increase anagrelide exposure; monitor for cardiovascular events and adjust dose.
Source: NLP:anagrelide hydrochloride
Strong CYP1A2 inhibitor that increases asenapine exposure. Full therapeutic doses expected to cause greater increase in asenapine exposure.
Source: NLP:asenapine
CYP3A4 inhibitor that increases carbamazepine plasma levels. Close monitoring of carbamazepine levels and dosage adjustment may be required.
Source: NLP:carbamazepine
Strong CYP2C19 inhibitor that may increase exposure to N-desmethylclobazam active metabolite, increasing risk of dose-related adverse reactions.
Source: NLP:clobazam
Weakness, hyperreflexia, and incoordination may occur rarely with coadministration of selective serotonin reuptake inhibitors.
Source: NLP:dihydroergotamine mesylate
Significant CYP3A inhibitor; estazolam should be used with caution and appropriate dosage reduction may be needed.
Source: NLP:estazolam
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:fosphenytoin sodium
Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations; monitor for increased adverse effects including QTc prolongation.
Source: NLP:haloperidol decanoate
Combined CYP3A4 and CYP2D6 inhibitor that increases haloperidol plasma concentrations, raising risk of adverse events including QTc prolongation.
Source: NLP:haloperidol lactate
Potent CYP2D6 inhibitor may increase plasma concentration of metoprolol, decreasing cardioselectivity.
Source: NLP:metoprolol
Potent CYP2D6 inhibitor may increase metoprolol plasma concentration, decreasing cardioselectivity.
Source: NLP:metoprolol tartrate
CYP1A2 inhibitor that decreases mexiletine clearance by 38%, requiring dose titration.
Source: NLP:mexiletine hydrochloride
CYP1A2 inhibitor decreases olanzapine clearance, increasing Cmax by 54% (female nonsmokers) to 77% (male smokers); lower olanzapine doses recommended.
Source: NLP:olanzapine
May increase olanzapine levels; lower dose of olanzapine component should be considered.
Source: NLP:olanzapine and fluoxetine
Fluvoxamine decreases olanzapine clearance, increasing olanzapine Cmax by 54-77% and AUC by 52-108%. Lower olanzapine doses should be considered.
Source: NLP:olanzapine pamoate
Strong CYP1A2 inhibitor that may increase exposure to pentoxifylline.
Source: NLP:pentoxifylline
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:extended phenytoin sodium
CYP1A2 and CYP2C19 substrate/inhibitor that may increase blood levels and/or toxicity of propranolol.
Source: NLP:propranolol hydrochloride
CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.
Source: NLP:riluzole
CYP3A4 and CYP1A2 inhibitor that increases roflumilast systemic exposure and may result in increased adverse reactions.
Source: NLP:roflumilast
Data from clinical studies of similar benzodiazepines suggest possible drug interaction with triazolam. Caution recommended.
Source: NLP:triazolam
In vitro studies suggest fluvoxamine inhibits the hydroxylation of bupropion; no clinical studies performed to evaluate this finding.
Source: NLP:bupropion hydrochloride
CYP2C19 inhibitor that could increase carisoprodol exposure and decrease meprobamate exposure. Full pharmacological impact is unknown.
Source: NLP:carisoprodol